



4555 Mansell Road, Suite 300, Alpharetta,
GA 30022
Tel: +1 (844) 884 5367
Email: info@vtivision.com
www.vtvision.com
www.vtvisioninvestors.com (for investors)

ASX Announcement

Visioneering Technologies, Inc. Appendix 4C and Cash Flow Report

Atlanta, Georgia, USA 28 April 2017: Visioneering Technologies, Inc (ASX: VTI), a US-based medical device company ('Visioneering' or 'The Company') engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue™ Multifocal 1 Day (NaturalVue MF) contact lenses has today released its Appendix 4C - Quarterly Cash Flow for the period ended March 31, 2017.

In the Company's first quarterly report since initiation of trading on the Australian Securities Exchange (ASX) on 28 March 2017, Visioneering reported sales revenue of US\$112,705 for the quarter, an increase of 42 per cent over the previous quarter (Q4 2016: US\$79,459).

The number of active accounts (customers purchasing during the quarter) increased from 134 at the end of Q4 2016, to 186 at the end of Q1 2017.

Net operating cash outflow was US\$2,180,000. Cash receipts from customers for the quarter were US\$86,000, and cash on hand was US\$26,891,000, following the A\$33.3 million (approximately US\$25 million) raising in the Initial Public Offer (IPO).

"We are off to a sprinting start on our US market expansion," said Dr Stephen Snowdy, CEO and Executive Director of Visioneering. "As foreshadowed in the IPO prospectus, we plan to build out our US sales force to 45 sales representatives over the next 12 months, which will provide the sales resources to capitalise on the pent-up demand for NaturalVue MF contact lenses and execute on our growth trajectory."

In line with Visioneering's plan to broaden and accelerate its US launch of NaturalVueMF contact lenses, it has recently appointed a new District Sales Manager for the western United States and added 10 new sales representatives across the country.

These highly-experienced additions to the sales team will cover Northern and Southern California (San Francisco, Sacramento, Los Angeles and San Diego), the northeastern United States (including greater metro New York City), as well as Cincinnati, Ohio and the Raleigh-Durham Research Triangle Area. The new sales personnel are expected to commence on-boarding accounts in Q2 2017 and generating revenue in Q3 2017.

Visioneering's Senior Vice-President of Sales and Marketing, Tony Sommer, stated The Company was delighted with the seniority and depth of experience the new hires bring to VTI.

Mr Sommer added, "Our recent successful IPO has continued to heighten awareness and interest in NaturalVueMF. The growth of our sales force from five to 16 personnel enables us to connect with

more practitioners and patients to increase our sales coverage and strengthen our commercialisation efforts across the country. We expect to make a number of additional sales force hires over the coming weeks.”

For more information, please contact:

<i>Company</i>	<i>Investor and media relations</i>
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: ssnowdy@vtivision.com	Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au

About VTI:

Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue™ Multifocal (MF) contact lens. The NaturalVue MF contact lens employs VTI’s Neurofocus Optics™ technology, which was developed, refined and tested over many years. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

NaturalVue lenses were cleared by the FDA in late 2014 and VTI recently commenced its US market expansion for NaturalVue MF contact lenses, following a successful pilot US market launch in 2015 and 2016. . VTI also sells and plans additional contact lens products.

Foreign ownership restrictions:

VTI’s CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are ‘restricted securities’ under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a ‘FOR US’ designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

MKT-VTI-PR21 r1